Literature DB >> 11325656

The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.

L Pagano, L Mele, M T Voso, P Chiusolo, R Putzulu, S Mazzotta, G Leone.   

Abstract

A topotecan/cytarabine combination has been reported to be effective in patients with myelodysplastic syndromes. We report our experience with this regimen in 12 patients with relapsed or secondary acute myeloid leukemia. Extra-hematologic toxicity was low, but the response to the treatment was very poor. In our opinion, this association is not a treatment option for these patients, but the addition of other agents could improve this results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325656

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  1 in total

1.  The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.

Authors:  Elisabeth J Walsby; Steven J Coles; Steven Knapper; Alan K Burnett
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.